LATEST
Israeli Soldiers Describe How Palestinian Families Came to Be Counted as ‘Collateral Damage’Myanmar Genocide Ruling Challenges Israel’s Defence of Its War in GazaSpain’s Marina Escobar Wins the Islantilla Open, the LET Access Series Season FinaleCHASING CanFish F2, the World's First 3-In-1 AI Fishing Scout, Officially Launches on KickstarterPatrick Manser and Evan Luthra Break Ground on BANURU Resort & Residences in ZanzibarIDMERIT Named as Highest-Ranked Identity Verification (IDV) Company on the Inc. 5000 List of America's Fastest-Growing Private CompaniesSophie Bert Leads the Islantilla Open After a Day of Fog, Rain and WindGladia Launches Gladia Connect and Gladia Agency‘I Still Love You, Pal’: Biden’s Secret Farewell Praise for Netanyahu Exposes Contradictions Over Gaza WarSPACECOOL Launches “SPACECOOL Heat Shield VT,” Featuring Zero-Energy Radiative Cooling Technology, on Kickstarter “Carry Your Own Tree Shade” — An Innovative Japanese Product Combining Advanced Cooling Technology with Portable Sun ProtectionIsraeli Soldiers Describe How Palestinian Families Came to Be Counted as ‘Collateral Damage’Myanmar Genocide Ruling Challenges Israel’s Defence of Its War in GazaSpain’s Marina Escobar Wins the Islantilla Open, the LET Access Series Season FinaleCHASING CanFish F2, the World's First 3-In-1 AI Fishing Scout, Officially Launches on KickstarterPatrick Manser and Evan Luthra Break Ground on BANURU Resort & Residences in ZanzibarIDMERIT Named as Highest-Ranked Identity Verification (IDV) Company on the Inc. 5000 List of America's Fastest-Growing Private CompaniesSophie Bert Leads the Islantilla Open After a Day of Fog, Rain and WindGladia Launches Gladia Connect and Gladia Agency‘I Still Love You, Pal’: Biden’s Secret Farewell Praise for Netanyahu Exposes Contradictions Over Gaza WarSPACECOOL Launches “SPACECOOL Heat Shield VT,” Featuring Zero-Energy Radiative Cooling Technology, on Kickstarter “Carry Your Own Tree Shade” — An Innovative Japanese Product Combining Advanced Cooling Technology with Portable Sun Protection
Health

Forward Pharma Initiates Phase II Efficacy and Safety Trial for FP187

Illustration: greatreporter

A randomised, double blind, placebo controlled efficacy and safety trial of different doses/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis.

Forward Pharma, A/S through its wholly owned German subsidiary Forward Pharma GmbH, today announced initiation of its first phase II trial investigating efficacy and safety of different doses and regimes of FP187 in a double blind, placebo controlled trial.

The trial is running in 18 centers in Germany and is foreseen to include at least 180 patients with moderate to severe plaque psoriasis. This study will compare the efficacy and safety of different doses and dose regimens of FP187 on the proportion of patients achieving PASI 75 (reduction in the PASI score of 75% from baseline), and several other secondary endpoints including Quality of Life. The Company expects data to be available Q3, 2011.

FP187 is an oral small molecule that demonstrated promising pharmacokinetics and good tolerability in Phase I testing in healthy volunteers. Following scientific advice meetings with the German Heath Authorities (BfArM), Forward Pharma GmbH received approval from the agency and ethics committees in August, 2010 for the current Phase II study.

Forward Pharma A/S is a privately held biotech company headquartered in Copenhagen, Denmark with an operational subsidiary in the BioCity campus of Leipzig, Germany.

http://www.forward-pharma.com

Related articles

Top